Spectrometry News and Research

RSS

Minnesota Governor signs into law the Tobacco Modernization and Compliance Act of 2010

Today Minnesota's leading health groups applauded Governor Tim Pawlenty for taking another step to protect youth from harmful tobacco products. This afternoon, the Governor signed into law the Tobacco Modernization and Compliance Act of 2010, which updates Minnesota laws to address new generations of tobacco products.

12 May 2010

International Dairy Foods Association issues statement on Childhood Obesity Report

The International Dairy Foods Association issued the following statement by Connie Tipton, president and CEO, regarding today's Report to the President by the White House Task Force on Childhood Obesity:

12 May 2010

OriGene Technologies, ISB to create proteotypic PeptideAtlas and SRM/MRM mass spectrometry standard database

OriGene Technologies, Inc., a leading gene-centric life sciences company, and the Institute for Systems Biology (ISB), announce plans to create a proteotypic PeptideAtlas and develop an SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry standard database for 5,000 human proteins. The new collaboration will apply ISB's novel systems biology mass spectrometry expertise to OriGene's large collection of full length human proteins.

12 May 2010

Researchers develop new method for tracing carbon flux

Microbial communities are performing important functions all around us - from the earth in our flowerpots to the human gut. Now researchers have developed a method for studying the metabolic functions of microbial communities in detail.

12 May 2010

Brookdale Senior Living announces sale of 10,000,000 shares by Fortress Investment Group affiliates

Brookdale Senior Living Inc. announced today the sale of an aggregate of 10,000,000 shares of its common stock by certain affiliates of Fortress Investment Group LLC. The Company will not sell any shares in the offering and will not receive any of the proceeds from the offering. Subject to customary conditions, the offering is expected to close on May 17, 2010.

12 May 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

Cardiome Pharma records $15.5M net income for first-quarter 2010

Cardiome Pharma Corp. today reported financial results for the first quarter ended March 31, 2010. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP).

12 May 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBiotechnologies Ltd., a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration to market its lead product, Occlusin 500 Artificial Embolization Device in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours.

12 May 2010

Tianyin third-quarter revenue up 60%

Tianyin Pharmaceutical Co., Inc.,, a biopharmaceutical company that specializes in the modernized traditional Chinese medicine and branded generics today announced fiscal results for its third quarter ended March 31, 2010.

12 May 2010

Potential new drug therapies for treatment of tuberculosis

Tuberculosis (TB) has been present in humans since ancient times. The origins of the disease date back to the first domestication of cattle, and skeletal remains show prehistoric humans (4,000 B.C.) had TB. Although relatively rare in the United States, it is the single leading bacterial cause of death worldwide. Approximately 8 million people are infected each year and 2 million people die from TB.

11 May 2010

Swedish scientists discover a new method to develop effective antimalarial drugs

Amodiaquine was introduced as an antimalarial drug, but was withdrawn when serious adverse effects were observed. Scientists at the University of Gothenburg, Sweden, have now developed a method that can be used to develop safer drugs.

10 May 2010

NHLBI grants MU $8.47 million for research on cardiovascular diseases

One of the largest medical research grants ever awarded to the University of Missouri was announced today by MU scientists and administrators. The National Institutes of Health grant will help answer important questions about such prevalent health problems as high blood pressure, diabetes and stroke. The conditions are closely associated with cardiovascular disease, which is the leading cause of death in Missouri and the nation.

7 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced non-small cell lung cancer.

3 May 2010

Researchers develop new diagnostic approach to fight against Chagas disease

Chagas disease is one of the most deadly parasitic diseases in the world. It affects more than 10 million people, primarily in the Americas. In South America alone it kills 50 000 people each year. A reliable and rapid diagnosis is the key in the battle against infection but until now, this has been next to impossible.

28 Apr 2010

Life Technologies first-quarter non-GAAP 2010 revenue increases 13% to $887 million

Life Technologies Corporation today announced results for its first quarter ending March 31, 2010. Non-GAAP revenue for the first quarter was $887 million, an increase of 13 percent over the $785 million reported for the first quarter of 2009. Excluding the impact of currency and completed acquisitions and divestitures, organic revenue for the quarter grew 10 percent over the same period in the previous year.

28 Apr 2010

Waters first-quarter sales increases 10% to $368 million

Waters Corporation reported first quarter 2010 sales of $368 million, an increase of 10% from sales of $333 million in the first quarter of 2009. In the quarter, foreign currency translation increased sales growth rate by 4% and, on a currency neutral basis, sales increased by 6% in comparison to the prior year's first quarter sales. On a GAAP basis, earnings per diluted share (E.P.S.) for the first quarter of 2010 were $0.79, compared to $0.75 for the first quarter of 2009.

27 Apr 2010

Trinean launches DropSense96 and DropPlate 16 G for genomic DNA quantification

Only 6 months after the release of its ground-breaking DropSense 96 spectrophotometer, Trinean, pioneer in high throughput analysis of droplets of samples in microfluidic structures, is now launching another device that will set the tone in scientific circles: the DropPlate 16 G. This upgrade of the current microfluid disposable, the DropPlate 16 U, allows researchers to quantify 96 DNA/RNA samples of only 2 microl in less than 5 minutes.

24 Apr 2010

AB SCIEX to collaborate in disease studies with Samuel Lunenfeld Research Institute of Mount Sinai Hospital

AB SCIEX, a global leader in life science analytical technologies, today announced that it is collaborating with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, one of the world's leading centers for biomedical research, to improve disease studies. The project is focused on better understanding cancer, diabetes and heart disease by advancing the study of proteins through the use of an emerging mass spectrometry platform currently under development by AB SCIEX.

22 Apr 2010

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

Hepatic fibrosis (HF) occurs in most types of chronic liver diseases and approximately 25%-40% of HF cases may ultimately progress to hepatic cirrhosis. Hepatic stellate cells (HSCs) contribute significantly to the occurrence of HF and the activation of HSC is the key issue in the pathogenesis of HF. Taurine is a kind of important anti-injury substance in the body.

21 Apr 2010

Spectrometry News and Research

Minnesota Governor signs into law the Tobacco Modernization and Compliance Act of 2010

International Dairy Foods Association issues statement on Childhood Obesity Report

OriGene Technologies, ISB to create proteotypic PeptideAtlas and SRM/MRM mass spectrometry standard database

Researchers develop new method for tracing carbon flux

Brookdale Senior Living announces sale of 10,000,000 shares by Fortress Investment Group affiliates

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Cardiome Pharma records $15.5M net income for first-quarter 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

Tianyin third-quarter revenue up 60%

Potential new drug therapies for treatment of tuberculosis

Swedish scientists discover a new method to develop effective antimalarial drugs

NHLBI grants MU $8.47 million for research on cardiovascular diseases

RayBiotech announces biomarker grant winners

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

Researchers develop new diagnostic approach to fight against Chagas disease

Life Technologies first-quarter non-GAAP 2010 revenue increases 13% to $887 million

Waters first-quarter sales increases 10% to $368 million

Trinean launches DropSense96 and DropPlate 16 G for genomic DNA quantification

AB SCIEX to collaborate in disease studies with Samuel Lunenfeld Research Institute of Mount Sinai Hospital

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News